Class summary at a glance.

Every drug in the Selective Serotonin Reuptake Inhibitor (SSRI) class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 4tracked in Part D
CY24 Part D spend: $334.8Mcombined across class
Total Rx claims: 29.6M7.4M unique beneficiaries
Generic mfrs (active): 34across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Sertraline

Brand: Zoloft · 24.4M Part D claims (CY24) · 6.0M beneficiaries · First FDA approval: 1992-02-11

18 generic mfrs 0 plans require PA

Low NADAC$0.032

→

Avg plan cost$1.27

Part D spend $247.4M 40× spread, current vs floor

Class share

74%

of class CY24 spend

View profile →

Paroxetine

Brand: BRISDELLE · 5.2M Part D claims (CY24) · 1.3M beneficiaries · First FDA approval: 2003-07-30

2 generic mfrs 686 plans require PA

Low NADAC$0.066

→

Avg plan cost$0.356

Part D spend $87.4M 5× spread, current vs floor

Class share

26%

of class CY24 spend

View profile →

Citalopram

Brand: CITALOPRAM HYDROBROMIDE · — Part D claims (CY24) · First FDA approval: 1998-07-17

Brand-only (no generics) 1 plans require PA

Low NADAC$0.026

→

Avg plan cost$0.640

Part D spend — 25× spread, current vs floor

Class share

of class CY24 spend

View profile →

Escitalopram

Brand: Lexapro · — Part D claims (CY24) · First FDA approval: 2002-08-14

14 generic mfrs 9 plans require PA

Low NADAC$0.041

→

Avg plan cost$0.882

Part D spend — 22× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.